In summary, our study compared the structure and flow between patients with MS and those with AQP4‐IgG‐positive NMOSD, indicating pathophysiological differences between them and suggesting that OCTA may have an additive effect as a biomarker in conjunction with routine OCT measurements. This evidence concerns the gene AQP4 and myeloid sarcoma.